Teva has relinquished all rights to cardiovascular applications of Mesoblast’s mesenchymal precursor cell (MPC) technology, as it focuses on its core CNS and respiratory interests. Mesoblast will seek a new partner with a cardiovascular focus at the appropriate time. It has entered an A$120m (~US$90m) equity finance facility with Kentgrove Capital to fund the ongoing Phase III CHF trial and a 600-patient confirmatory trial (estimated cost ~US$90m), and has brought forward the interim fu
08 Jul 2016
Teva returns rights to cardiovascular programme
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Teva returns rights to cardiovascular programme
Mesoblast Limited (MSB:ASX) | 0 0 -2.3% | Mkt Cap: 591.5m
- Published:
08 Jul 2016 -
Author:
Dr Dennis Hulme -
Pages:
15
Teva has relinquished all rights to cardiovascular applications of Mesoblast’s mesenchymal precursor cell (MPC) technology, as it focuses on its core CNS and respiratory interests. Mesoblast will seek a new partner with a cardiovascular focus at the appropriate time. It has entered an A$120m (~US$90m) equity finance facility with Kentgrove Capital to fund the ongoing Phase III CHF trial and a 600-patient confirmatory trial (estimated cost ~US$90m), and has brought forward the interim fu